ReviewImmunology2022
Double-negative T cells: Setting the stage for disease control or progression.
Review in Immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed.
- Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.Journal of hematology & oncology · 2024Trial
- Systems genetics analysis reveals immune mediators of coronavirus disease severity in mice.Genetics · 2026Article
- The Transcription Factor EGR2 Plays a Central Role in the Expansion and Function of TCRαβImmunology · 2026Article
- Spatial T lymphocyte infiltration into the primary melanoma tumor associates with survival.Melanoma research · 2026Article
- Integrated Single Cell Analysis Reveals the Transcriptional Heterogeneity of Mouse Double Negative T Cells.International journal of molecular sciences · 2026Article
- IFITM1 enhances anti-tumor function of unconventional TCRαβ double negative T cells by upregulating mitophagy.Science China. Life sciences · 2026Article
- Unconventional T cells in urological cancers: catch them if you can.Nature reviews. Urology · 2026Review
- Article
- Article
- Ketamine reduces microglial activation and brain monocyte infiltration and promotes peripheral regulatory immune cells, relieving lipopolysaccharide (LPS)-induced depressive-like behavior in mice.Molecular psychiatry · 2026Article
- Cross-coronavirus host susceptibility loci influence disease severity through immune mediators.bioRxiv : the preprint server for biology · 2026Article
- Multicellular origins of murine ovarian inflammaging.Communications biology · 2026Article
- Engineering Adaptive Immunity in 3D: A Patient-Specific Lymphoid Model Using Stromal Networks and Peripheral Blood Mononuclear Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Immune response in dogs with myxomatous mitral valve disease: insights into monocyte and lymphocyte subtypes and natural killer cells.Journal of veterinary internal medicine · 2026Article
- Increased CD95Frontiers in immunology · 2026Article
- Proliferative double-negative T (DNT)-cell responses to PD-1 blockade therapy were positively correlated with good clinical outcomes in non-small cell lung cancer patients.Pakistan journal of medical sciences · 2026Article
- Cross-tissue integrative transcriptomic and multimodal analyses suggest shared immune signatures linking lupus nephritis and cutaneous lupus erythematosus.Frontiers in immunology · 2026Article
- Double negative T cells (CD4Frontiers in immunology · 2026Article
- (TCRαβCells · 2025Review
- Immunocompetent Murine Models Recapitulate the Heterogeneous Tumor-Immune Microenvironment of Human Liposarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Double-negative (DN) T cells are present at relatively low frequencies in human peripheral blood, and are characterized as expressing the alpha-beta or gamma-delta T-cell receptor (TCR), but not the CD4 nor the CD8 co-receptors. Despite their low frequencies, these cells are potent producers of cytokines and, thus, are key orchestrators of immune responses. DN T cells were initially associated with induction of peripheral immunological tolerance and immunomodulatory activities related to disease prevention. However, other studies demonstrated that these cells can also display effector functions associated with pathology development. This apparent contradiction highlighted the heterogeneity of the DN T-cell population. Here, we review phenotypic and functional characteristics of DN T cells, emphasizing their role in human diseases. The need for developing biomarkers to facilitate the translation of studies from animal models to humans will also be discussed. Finally, we will examine DN T cells as promising therapeutic targets to prevent or inhibit human disease development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.